Endocannabinoid-mediated modulation of stress responses: physiological and pathophysiological significance.

[1]  D. Finn,et al.  Effects of intra‐basolateral amygdala administration of rimonabant on nociceptive behaviour and neuronal activity in the presence or absence of contextual fear , 2010, European journal of pain.

[2]  M. McCarthy,et al.  Differential effects of chronic unpredictable stress on hippocampal CB1 receptors in male and female rats , 2009, Behavioural Brain Research.

[3]  B. Gorzalka,et al.  Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress , 2009, Psychoneuroendocrinology.

[4]  Ryan K. Butler,et al.  Stress-induced analgesia , 2009, Progress in Neurobiology.

[5]  Á. Díaz,et al.  Altered CB1 receptor‐signaling in prefrontal cortex from an animal model of depression is reversed by chronic fluoxetine , 2009, Journal of neurochemistry.

[6]  F. Guimarães,et al.  Modulation of anxiety-like behaviour by Transient Receptor Potential Vanilloid Type 1 (TRPV1) channels located in the dorsolateral periaqueductal gray , 2009, European Neuropsychopharmacology.

[7]  J. Deussing,et al.  Endocannabinoids mediate acute fear adaptation via glutamatergic neurons independently of corticotropin‐releasing hormone signaling , 2009, Genes, brain, and behavior.

[8]  V. Marzo,et al.  Anxiolytic Effects in Mice of a Dual Blocker of Fatty Acid Amide Hydrolase and Transient Receptor Potential Vanilloid Type-1 Channels , 2009, Neuropsychopharmacology.

[9]  D. Finn,et al.  Endocannabinoid-mediated enhancement of fear-conditioned analgesia in rats: Opioid receptor dependency and molecular correlates , 2008, PAIN.

[10]  F. Pamplona,et al.  Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats , 2008, European Neuropsychopharmacology.

[11]  D. Pfaff,et al.  Brain mast cells link the immune system to anxiety-like behavior , 2008, Proceedings of the National Academy of Sciences.

[12]  D. Finn,et al.  Clinical correlates of stress-induced analgesia: Evidence from pharmacological studies , 2008, PAIN.

[13]  J. Rosenstock,et al.  SERENADE: The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients , 2008, Diabetes Care.

[14]  B. Gorzalka,et al.  Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents , 2008, Journal of Neural Transmission.

[15]  G. Gobbi,et al.  The cannabinoid CB1 receptor and the endocannabinoid anandamide: possible antidepressant targets , 2008, Expert opinion on therapeutic targets.

[16]  J. Kelly,et al.  Augmentation of endogenous cannabinoid tone modulates lipopolysaccharide‐induced alterations in circulating cytokine levels in rats , 2008, Immunology.

[17]  S. Doggrell.  Is rimonabant efficacious and safe in the treatment of obesity? , 2008, Expert opinion on pharmacotherapy.

[18]  G. Marsicano,et al.  Conditional cannabinoid receptor type 1 mutants reveal neuron subpopulation-specific effects on behavioral and neuroendocrine stress responses , 2008, Psychoneuroendocrinology.

[19]  R. McLaughlin,et al.  Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment , 2008, Journal of neurochemistry.

[20]  B. Gorzalka,et al.  Regulation of endocannabinoid signaling by stress: Implications for stress-related affective disorders , 2008, Neuroscience & Biobehavioral Reviews.

[21]  P. Massi,et al.  Expression and function of the endocannabinoid system in glial cells. , 2008, Current pharmaceutical design.

[22]  C. Fowler.  "The tools of the trade"--an overview of the pharmacology of the endocannabinoid system. , 2008, Current pharmaceutical design.

[23]  S. Tauber,et al.  CNS immune surveillance and neuroinflammation: endocannabinoids keep control. , 2008, Current pharmaceutical design.

[24]  Eiki Takahashi,et al.  Additive subthreshold dose effects of cannabinoid CB(1) receptor antagonist and selective serotonin reuptake inhibitor in antidepressant behavioral tests. , 2008, European journal of pharmacology.

[25]  F. Pamplona,et al.  Short- and long-term effects of cannabinoids on the extinction of contextual fear memory in rats , 2008, Neurobiology of Learning and Memory.

[26]  C. Stern,et al.  Attenuation of anxiety-related behaviour after the antagonism of transient receptor potential vanilloid type 1 channels in the rat ventral hippocampus , 2008, Behavioural pharmacology.

[27]  S. Eisenstein,et al.  An endocannabinoid signaling system modulates anxiety-like behavior in male Syrian hamsters , 2008, Psychopharmacology.

[28]  C. Hillard,et al.  Adaptations in endocannabinoid signaling in response to repeated homotypic stress: a novel mechanism for stress habituation , 2008, The European journal of neuroscience.

[29]  F. Holsboer,et al.  Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice , 2008, The Pharmacogenomics Journal.

[30]  V. Marzo,et al.  Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. , 2008, Cerebral cortex.

[31]  B. Lutz,et al.  The endocannabinoid system: emotion, learning and addiction , 2008, Addiction biology.

[32]  V. Marzo,et al.  Targeting the endocannabinoid system: to enhance or reduce? , 2008, Nature Reviews Drug Discovery.

[33]  A. Scheen,et al.  CB1 Receptor Blockade and its Impact on Cardiometabolic Risk Factors: Overview of the RIO Programme with Rimonabant , 2008, Journal of neuroendocrinology.

[34]  O. Ullrich,et al.  Endocannabinoids and the Brain Immune System: New Neurones at the Horizon? , 2008, Journal of neuroendocrinology.

[35]  D. Finn,et al.  Effects of chronic treatment with citalopram on cannabinoid and opioid receptor-mediated G-protein coupling in discrete rat brain regions , 2008, Psychopharmacology.

[36]  F. Guimarães,et al.  Activation of CB1 cannabinoid receptors in the dorsolateral periaqueductal gray reduces the expression of contextual fear conditioning in rats , 2008, Psychopharmacology.

[37]  B. Cravatt,et al.  Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. , 2008, Chemical reviews.

[38]  C. Ledent,et al.  BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice , 2008, Journal of neurochemistry.

[39]  T. Matsui,et al.  Stress‐induced analgesia in mice: evidence for interaction between endocannabinoids and cholecystokinin , 2008, The European journal of neuroscience.

[40]  B. Gorzalka,et al.  Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. , 2008, Pharmacopsychiatry.

[41]  D. Overstreet,et al.  Repeated Lipopolysaccharide (LPS) or Cytokine Treatments Sensitize Ethanol Withdrawal-Induced Anxiety-Like Behavior , 2008, Neuropsychopharmacology.

[42]  George R. Uhl,et al.  Brain Neuronal CB2 Cannabinoid Receptors in Drug Abuse and Depression: From Mice to Human Subjects , 2008, PloS one.

[43]  S. Eisenstein,et al.  Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia , 2008, Neuropharmacology.

[44]  B. Lutz,et al.  Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors , 2008, Neuropharmacology.

[45]  Leyu Shi,et al.  Effects of acute and repeated restraint stress on endocannabinoid content in the amygdala, ventral striatum, and medial prefrontal cortex in mice , 2008, Neuropharmacology.

[46]  F. Holsboer,et al.  Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice , 2008, Psychoneuroendocrinology.

[47]  D. Piomelli,et al.  The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition , 2008, Neuropharmacology.

[48]  R. Mangieri,et al.  Antidepressant-like Activity of the Fatty Acid Amide Hydrolase Inhibitor URB597 in a Rat Model of Chronic Mild Stress , 2007, Biological Psychiatry.

[49]  D. Finn,et al.  The effect of CB1 receptor antagonism in the right basolateral amygdala on conditioned fear and associated analgesia in rats , 2007, The European journal of neuroscience.

[50]  G. Marsicano,et al.  The endocannabinoid system in the processing of anxiety and fear and how CB1 receptors may modulate fear extinction. , 2007, Pharmacological research.

[51]  R. Mangieri,et al.  Enhancement of endocannabinoid signaling and the pharmacotherapy of depression. , 2007, Pharmacological research.

[52]  Stephen P. H. Alexander,et al.  The complications of promiscuity: endocannabinoid action and metabolism , 2007, British journal of pharmacology.

[53]  S. McMahon,et al.  Pathophysiology of Peripheral Neuropathic Pain: Immune Cells and Molecules , 2007, Anesthesia and analgesia.

[54]  B. Lutz.  The Endocannabinoid System and Extinction Learning , 2007, Molecular Neurobiology.

[55]  B. Leonard.  HPA and Immune Axes in Stress: Involvement of the Serotonergic System , 2007, Neuroimmunomodulation.

[56]  B. Gorzalka,et al.  Estrogen recruits the endocannabinoid system to modulate emotionality , 2007, Psychoneuroendocrinology.

[57]  C. Hillard,et al.  Interactions between endocannabinoids and stress-induced decreased sensitivity to natural reward , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[58]  D. Cota,et al.  Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function. , 2007, Endocrinology.

[59]  A. Miller,et al.  Endogenous glucocorticoids protect against TNF-alpha-induced increases in anxiety-like behavior in virally infected mice , 2007, Molecular Psychiatry.

[60]  I. Galve-Roperh,et al.  The Endocannabinoid System and Neurogenesis in Health and Disease , 2007, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[61]  K. Ressler,et al.  Modulation of Fear and Anxiety by the Endogenous Cannabinoid System , 2007, CNS Spectrums.

[62]  B. Cravatt,et al.  Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality , 2007, Psychopharmacology.

[63]  F. Holsboer,et al.  Reduced Anxiety, Conditioned Fear, and Hippocampal Long-Term Potentiation in Transient Receptor Potential Vanilloid Type 1 Receptor-Deficient Mice , 2007, The Journal of Neuroscience.

[64]  S. Ben-Shabat,et al.  Antidepressant-induced undesirable weight gain: prevention with rimonabant without interference with behavioral effectiveness. , 2007, European journal of pharmacology.

[65]  A. Thorpe,et al.  The disruptive effects of the CB1 receptor antagonist rimonabant on extinction learning in mice are task-specific , 2007, Psychopharmacology.

[66]  G. Gessa,et al.  Anxiolytic-Like Properties of the Anandamide Transport Inhibitor AM404 , 2006, Neuropsychopharmacology.

[67]  G. Nomikos,et al.  Cannabinoid CB1 receptor antagonism modulates plasma corticosterone in rodents. , 2006, European journal of pharmacology.

[68]  J. Kelly,et al.  In vivo modulation of LPS-induced alterations in brain and peripheral cytokines and HPA axis activity by cannabinoids , 2006, Journal of Neuroimmunology.

[69]  A. Hohmann,et al.  Endocannabinoid mechanisms of pain modulation , 2006, The AAPS Journal.

[70]  C. André,et al.  Rimonabant for overweight or obesity. , 2006, The Cochrane database of systematic reviews.

[71]  K. Vinod,et al.  Role of the endocannabinoid system in depression and suicide. , 2006, Trends in pharmacological sciences.

[72]  P. Pacher,et al.  The Endocannabinoid System as an Emerging Target of Pharmacotherapy , 2006, Pharmacological Reviews.

[73]  Lisa M. Shin,et al.  Neurocircuitry Models of Posttraumatic Stress Disorder and Extinction: Human Neuroimaging Research—Past, Present, and Future , 2006, Biological Psychiatry.

[74]  D. Tracey,et al.  Immune and inflammatory mechanisms in neuropathic pain , 2006, Brain Research Reviews.

[75]  G. Uhl,et al.  Discovery of the Presence and Functional Expression of Cannabinoid CB2 Receptors in Brain , 2006, Annals of the New York Academy of Sciences.

[76]  P. Massi,et al.  Cannabinoids, immune system and cytokine network. , 2006, Current pharmaceutical design.

[77]  Beat Lutz,et al.  Cannabinoid CB1 Receptor Mediates Fear Extinction via Habituation-Like Processes , 2006, The Journal of Neuroscience.

[78]  S. Di,et al.  Opposing Crosstalk between Leptin and Glucocorticoids Rapidly Modulates Synaptic Excitation via Endocannabinoid Release , 2006, The Journal of Neuroscience.

[79]  David J Bucci,et al.  Blockade of cannabinoid CB1 receptors alters contextual learning and memory. , 2006, European journal of pharmacology.

[80]  L. Jara,et al.  Immune-Neuroendocrine Interactions and Autoimmune Diseases , 2006, Clinical & developmental immunology.

[81]  G. Velasco,et al.  Endocannabinoids: a new family of lipid mediators involved in the regulation of neural cell development. , 2006, Current pharmaceutical design.

[82]  B. Gorzalka,et al.  Involvement of the Endocannabinoid System in the Ability of Long-Term Tricyclic Antidepressant Treatment to Suppress Stress-Induced Activation of the Hypothalamic–Pituitary–Adrenal Axis , 2006, Neuropsychopharmacology.

[83]  T. Freund,et al.  The effects of cannabinoids on contextual conditioned fear in CB1 knockout and CD1 mice , 2006, Behavioural pharmacology.

[84]  A. Hohmann,et al.  Role of the basolateral nucleus of the amygdala in endocannabinoid-mediated stress-induced analgesia , 2006, Neuroscience Letters.

[85]  R. Pertwee.  The pharmacology of cannabinoid receptors and their ligands: an overview , 2006, International Journal of Obesity.

[86]  A. Hohmann,et al.  Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia , 2006, Neuropharmacology.

[87]  T. Klein,et al.  Cannabinoid-Induced Immune Suppression and Modulation of Antigen-Presenting Cells , 2006, Journal of Neuroimmune Pharmacology.

[88]  G. Uhl,et al.  Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain , 2006, Brain Research.

[89]  C. Vaughan.  Stressed-out endogenous cannabinoids relieve pain. , 2006, Trends in pharmacological sciences.

[90]  T. Cassano,et al.  Correction for Gobbi et al., Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[91]  G. Cabral,et al.  Cannabinoid receptors in microglia of the central nervous system: immune functional relevance , 2005, Journal of leukocyte biology.

[92]  B. Gorzalka,et al.  Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test , 2005, European Neuropsychopharmacology.

[93]  A. Hohmann,et al.  Inhibition of fatty-acid amide hydrolase enhances cannabinoid stress-induced analgesia: Sites of action in the dorsolateral periaqueductal gray and rostral ventromedial medulla , 2005, Neuropharmacology.

[94]  B. Roques,et al.  CB1 receptor knockout mice show similar behavioral modifications to wild-type mice when enkephalin catabolism is inhibited , 2005, Brain Research.

[95]  S. Di,et al.  Rapid glucocorticoid-mediated endocannabinoid release and opposing regulation of glutamate and gamma-aminobutyric acid inputs to hypothalamic magnocellular neurons. , 2005, Endocrinology.

[96]  S. Maier,et al.  Central Proinflammatory Cytokines and Pain Enhancement , 2005, Neurosignals.

[97]  O. Valverde.  Participation of the cannabinoid system in the regulation of emotional-like behaviour. , 2005, Current pharmaceutical design.

[98]  R. Mechoulam,et al.  Differential response to acute and repeated stress in cannabinoid CB1 receptor knockout newborn and adult mice , 2005, Behavioural pharmacology.

[99]  B. Gorzalka,et al.  Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? , 2005, Behavioural pharmacology.

[100]  J. Borrell,et al.  The role of cannabinoid system on immune modulation: therapeutic implications on CNS inflammation. , 2005, Mini reviews in medicinal chemistry.

[101]  C. Wotjak.  Role of endogenous cannabinoids in cognition and emotionality. , 2005, Mini reviews in medicinal chemistry.

[102]  J. Crystal,et al.  An endocannabinoid mechanism for stress-induced analgesia , 2005, Nature.

[103]  S. File,et al.  Endocannabinoid system and stress and anxiety responses , 2005, Pharmacology Biochemistry and Behavior.

[104]  Stephen B. McMahon,et al.  Immune and glial cell factors as pain mediators and modulators , 2005, Experimental Neurology.

[105]  B. Gorzalka,et al.  Downregulation of Endocannabinoid Signaling in the Hippocampus Following Chronic Unpredictable Stress , 2005, Neuropsychopharmacology.

[106]  S. Maier,et al.  Immune-to-brain communication dynamically modulates pain: Physiological and pathological consequences , 2005, Brain, Behavior, and Immunity.

[107]  Michael Davis,et al.  Enhancing Cannabinoid Neurotransmission Augments the Extinction of Conditioned Fear , 2005, Neuropsychopharmacology.

[108]  B. Cravatt,et al.  Synergistic Interactions between Cannabinoids and Environmental Stress in the Activation of the Central Amygdala , 2005, Neuropsychopharmacology.

[109]  C. Hillard,et al.  Inhibition of restraint stress‐induced neural and behavioural activation by endogenous cannabinoid signalling , 2005, The European journal of neuroscience.

[110]  M. Wichers,et al.  Cytokines and major depression , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[111]  G. Griebel,et al.  Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents , 2005, Biological Psychiatry.

[112]  C. Ledent,et al.  CB1 Receptor Knockout Mice Display Reduced Ethanol-Induced Conditioned Place Preference and Increased Striatal Dopamine D2 Receptors , 2005, Neuropsychopharmacology.

[113]  W. Cullinan,et al.  Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. , 2004, Endocrinology.

[114]  C. Ledent,et al.  The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice. , 2004, Life sciences.

[115]  D. Finn,et al.  Evidence for differential modulation of conditioned aversion and fear‐conditioned analgesia by CB1 receptors , 2004, The European journal of neuroscience.

[116]  G. Nomikos,et al.  Genetic deletion and pharmacological blockade of CB1 receptors modulates anxiety in the shock‐probe burying test , 2004, The European journal of neuroscience.

[117]  T. Dinan,et al.  Cytokines: abnormalities in major depression and implications for pharmacological treatment , 2004, Human psychopharmacology.

[118]  T. Freund,et al.  CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents , 2004, Behavioural pharmacology.

[119]  J. Manzanares,et al.  Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors , 2004, Neuropharmacology.

[120]  Alcino J. Silva,et al.  Memory Reconsolidation and Extinction Have Distinct Temporal and Biochemical Signatures , 2004, The Journal of Neuroscience.

[121]  M. Cascio,et al.  Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence. , 2004, Drug and alcohol dependence.

[122]  C. Sommer,et al.  Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia , 2004, Neuroscience Letters.

[123]  T. Freund,et al.  Context‐dependent effects of CB1 cannabinoid gene disruption on anxiety‐like and social behaviour in mice , 2004, The European journal of neuroscience.

[124]  Á. Pazos,et al.  Influence of age, postmortem delay and freezing storage period on cannabinoid receptor density and functionality in human brain , 2004, Neuropharmacology.

[125]  D. Finn,et al.  Cannabinoids modulate ultrasound-induced aversive responses in rats , 2004, Psychopharmacology.

[126]  B. Rocha,et al.  Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice , 2003, Behavioural pharmacology.

[127]  T. Croci,et al.  Role of cannabinoid CB1 receptors and tumor necrosis factor‐α in the gut and systemic anti‐inflammatory activity of SR 141716 (Rimonabant) in rodents , 2003, British journal of pharmacology.

[128]  S. Di,et al.  Nongenomic Glucocorticoid Inhibition via Endocannabinoid Release in the Hypothalamus: A Fast Feedback Mechanism , 2003, The Journal of Neuroscience.

[129]  J. Haller,et al.  ‘One‐trial sensitization’ to the anxiolytic‐like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus‐maze , 2003, The European journal of neuroscience.

[130]  K. Mackie,et al.  Nonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration , 2003, The Journal of Neuroscience.

[131]  K. Perry,et al.  The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions , 2003, British journal of pharmacology.

[132]  M. Wichers,et al.  The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. , 2002, The international journal of neuropsychopharmacology.

[133]  T. Freund,et al.  The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety , 2002, The European journal of neuroscience.

[134]  W. Zieglgänsberger,et al.  The endogenous cannabinoid system controls extinction of aversive memories , 2002, Nature.

[135]  T. Freund,et al.  Brain monoglyceride lipase participating in endocannabinoid inactivation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[136]  R. Nicoll,et al.  Endocannabinoid Signaling in the Brain , 2002, Science.

[137]  M. Parmentier,et al.  Age‐related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour , 2002, The European journal of neuroscience.

[138]  M. Parmentier,et al.  Involvement of CB1 cannabinoid receptors in emotional behaviour , 2002, Psychopharmacology.

[139]  G. Denhardt,et al.  The anti-inflammatory activities of cannabinoid receptor ligands in mouse peritonitis models. , 2001, European journal of pharmacology.

[140]  J. Fernández-Ruiz,et al.  Effects of cannabinoids on adrenaline release from adrenal medullary cells , 2001, British journal of pharmacology.

[141]  S. Rivest.  How circulating cytokines trigger the neural circuits that control the hypothalamic–pituitary–adrenal axis , 2001, Psychoneuroendocrinology.

[142]  S. Ben-Shabat,et al.  An endogenous cannabinoid (2-AG) is neuroprotective after brain injury , 2001, Nature.

[143]  R. Miguel,et al.  Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters , 2001, Pharmacology Biochemistry and Behavior.

[144]  G. Denhardt,et al.  Modulation of cytokine responses in Corynebacterium parvum-primed endotoxemic mice by centrally administered cannabinoid ligands. , 2001, European journal of pharmacology.

[145]  L. Petrocellis,et al.  Anandamide: some like it hot. , 2001, Trends in pharmacological sciences.

[146]  B. Leonard.  The immune system, depression and the action of antidepressants , 2001, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[147]  A. Finazzi-Agro’,et al.  The Activity of Anandamide at Vanilloid VR1 Receptors Requires Facilitated Transport across the Cell Membrane and Is Limited by Intracellular Metabolism* , 2001, The Journal of Biological Chemistry.

[148]  V. Di Marzo,et al.  Structure‐activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens , 2001, British journal of pharmacology.

[149]  T. Bisogno,et al.  Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin‐like activity , 2000, FEBS letters.

[150]  P. Zygmunt,et al.  The anandamide transport inhibitor AM404 activates vanilloid receptors. , 2000, European journal of pharmacology.

[151]  G. Denhardt,et al.  Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. , 2000, The Journal of pharmacology and experimental therapeutics.

[152]  M. Parmentier,et al.  Reduction of stress‐induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors , 2000, The European journal of neuroscience.

[153]  J. Chambers,et al.  The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1) , 2000, British journal of pharmacology.

[154]  M. Hatzinger.  Neuropeptides and the Hypothalamic-Pituitary-Adrenocortical (HPA) System: Review of Recent Research Strategies in Depression , 2000, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[155]  A. Dunn.  Cytokine Activation of the HPA Axis , 2000, Annals of the New York Academy of Sciences.

[156]  J. Buckingham,et al.  Regulation of the hypothalamo-pituitary-adrenal axis by cytokines. , 1999, Bailliere's best practice & research. Clinical endocrinology & metabolism.

[157]  Wenger,et al.  Immunocytochemical Demonstration of CB1 Cannabinoid Receptors in the Anterior Lobe of the Pituitary Gland , 1999, Journal of neuroendocrinology.

[158]  A. Chakrabarti,et al.  In-Vitro and In-Vivo Action of Cannabinoids , 1999, Neurochemical Research.

[159]  J. Manzanares,et al.  Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of Δ9-tetrahydrocannabinol in rats , 1999, Brain Research.

[160]  D. Julius,et al.  Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide , 1999, Nature.

[161]  D. Parolaro.  Presence and functional regulation of cannabinoid receptors in immune cells. , 1999, Life sciences.

[162]  M. Parmentier,et al.  Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. , 1999, Science.

[163]  A. Chakrabarti,et al.  Neurobehavioral Effects of Anandamide and Cannabinoid Receptor Gene Expression in Mice , 1998, Brain Research Bulletin.

[164]  K. Mackie,et al.  Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system , 1998, Neuroscience.

[165]  B. Leonard,et al.  Depression, stress and immunological activation: the role of cytokines in depressive disorders. , 1998, Life sciences.

[166]  J. Macher,et al.  HPA axis dysfunction in depression: Correlation with monoamine system abnormalities , 1997, Psychoneuroendocrinology.

[167]  É. Mezey,et al.  Expression of the CB1 and CB2 receptor messenger RNAs during embryonic development in the rat , 1997, Neuroscience.

[168]  D. Piomelli,et al.  A second endogenous cannabinoid that modulates long-term potentiation , 1997, Nature.

[169]  F. Rodríguez de Fonseca,et al.  Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety‐like responses in the rat , 1997, Neuroreport.

[170]  Stephen P. Mayfield,et al.  Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides , 1996, Nature.

[171]  R. E. Brown,et al.  Cannabinoid modulation of rat pup ultrasonic vocalizations. , 1996, European journal of pharmacology.

[172]  V. Di Marzo,et al.  Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. , 1996, The Biochemical journal.

[173]  G. Chrousos,et al.  The three-way interactions between the hypothalamic-pituitary-adrenal and gonadal axes and the immune system. , 1996, Bailliere's clinical rheumatology.

[174]  B. Skogseid,et al.  Intact adrenocorticotropic hormone secretion but impaired cortisol response in patients with active rheumatoid arthritis. Effect of glucocorticoids. , 1996, The Journal of rheumatology.

[175]  G. Chrousos,et al.  Hypothalamic-pituitary-adrenal-glucocorticoid axis function in rheumatoid arthritis. , 1996, The Journal of rheumatology.

[176]  N. Ueda,et al.  Partial Purification and Characterization of the Porcine Brain Enzyme Hydrolyzing and Synthesizing Anandamide (*) , 1995, The Journal of Biological Chemistry.

[177]  S. Galiègue,et al.  Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. , 1995, European journal of biochemistry.

[178]  F. Holsboer,et al.  Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? , 1995, Trends in Neurosciences.

[179]  E. Morand,et al.  Abnormal hypothalamic-pituitary-adrenal axis function in rheumatoid arthritis. Effects of nonsteroidal antiinflammatory drugs and water immersion. , 1994, Arthritis and rheumatism.

[180]  S. Savastano,et al.  Hypothalamic-pituitary-adrenal axis and immune system. , 1994, Acta neurologica.

[181]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[182]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[183]  G. Chrousos,et al.  The Stress Response and the Regulation of Inflammatory Disease , 1992, Annals of Internal Medicine.

[184]  G. Kingsley,et al.  Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis. , 1992, Arthritis and rheumatism.

[185]  M. Herkenham,et al.  Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[186]  H. Akil,et al.  Neuropeptide Concentrations in the Cerebrospinal Fluid of Depressed Patients Treated with Electroconvulsive Therapy , 1991, British Journal of Psychiatry.

[187]  T. Bonner,et al.  Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.

[188]  A. Howlett,et al.  Determination and characterization of a cannabinoid receptor in rat brain. , 1988, Molecular pharmacology.

[189]  G. Affleck,et al.  Attributional processes in rheumatoid arthritis patients. , 1987, Arthritis and rheumatism.

[190]  Z. Amit,et al.  Stress-induced analgesia: adaptive pain suppression. , 1986, Physiological reviews.

[191]  Martin Thomas,et al.  The tools of the trade , 2009 .

[192]  Alisa R Gutman,et al.  Functional Interactions between Endocannabinoid and CCK Neurotransmitter Systems May Be Critical for Extinction Learning , 2009, Neuropsychopharmacology.

[193]  C. Wotjak,et al.  Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis. , 2008, Progress in brain research.

[194]  D. Lovinger.  Presynaptic modulation by endocannabinoids. , 2008, Handbook of experimental pharmacology.

[195]  V. Di Marzo.  Endocannabinoids: synthesis and degradation. , 2008, Reviews of physiology, biochemistry and pharmacology.

[196]  G. Serra,et al.  Clinical Practice and Epidemiology in Mental Health a Possible Role for the Endocannabinoid System in the Neurobiology of Depression , 2007 .

[197]  Alan J. Thomas,et al.  Cytokines and late-life depression. , 2006, Essential psychopharmacology.

[198]  G. Uhl,et al.  Methods to study the behavioral effects and expression of CB2 cannabinoid receptor and its gene transcripts in the chronic mild stress model of depression. , 2006, Methods in molecular medicine.

[199]  V. Marzo.  Endocannabinoids: synthesis and degradation. , 2006 .

[200]  K. Mackie,et al.  Distribution of cannabinoid receptors in the central and peripheral nervous system. , 2005, Handbook of experimental pharmacology.

[201]  E. Fridea,et al.  Differential response to acute and repeated stress in cannabinoid CB1 receptor knockout newborn and adult mice , 2005 .

[202]  S. Maier,et al.  Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical pain. , 2003, Advances in experimental medicine and biology.

[203]  S. Gaetani,et al.  Modulation of anxiety through blockade of anandamide hydrolysis , 2003, Nature Medicine.

[204]  Reviews of Physiology Biochemistry and Pharmacology , 2000, Reviews of Physiology, Biochemistry and Pharmacology.

[205]  A. Turnbull,et al.  Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. , 1999, Physiological reviews.

[206]  H. Anisman,et al.  Anhedonic and anxiogenic effects of cytokine exposure. , 1999, Advances in experimental medicine and biology.

[207]  C. Nemeroff,et al.  The role of corticotropin-releasing factor in depression and anxiety disorders. , 1999, The Journal of endocrinology.

[208]  T. Sugiura,et al.  2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. , 1995, Biochemical and biophysical research communications.

[209]  R L Wilder,et al.  Neuroendocrine-immune system interactions and autoimmunity. , 1995, Annual review of immunology.

[210]  H. Anisman,et al.  Multiple neurochemical and behavioral consequences of stressors: implications for depression. , 1990, Pharmacology & therapeutics.

[211]  D. Hamilos.  Antigen presenting cells , 1989, Immunologic research.

[212]  Identification functional characterization of brainstem cannabinoid CB2 receptors. , 2022 .